Keith Regnante's departure as Chief Financial Officer of Keros Therapeutics, Inc. was reported, effective August 3, 2026; the filing names no successor. As of November 6, 2026, Keros Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 25, 2026 to July 22, 2026, naming 2 appointments and 1 departure (Form 8-K, July 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Keros Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Keros Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-25 to 2026-07-22. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Keros Therapeutics, Inc. files it.
Also on the record for Keros Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock Portfolio Management LLC | 9.1% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.4% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 5.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 6.9% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 10.1% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by D. E. Shaw & Co., L.P. | 3.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by ExodusPoint Capital Management, LP | 0.04% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Madison Avenue International LP | 2.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 5% of the class | 5%+ stakes | Source |
| November 18, 2025 | Stake report, Schedule 13G, by ExodusPoint Capital Management, LP | 6.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Keros Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Keros Therapeutics, Inc. and the records around it.
Keros Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- ExodusPoint Capital Management, LP also filed stake reports on 3 other companies: RE/MAX Holdings, Inc. (Aug 2026), SPRUCE BIOSCIENCES, INC. (Apr 2026), ALT5 Sigma Corp (Aug 2025)
- Pontifax Management 4 GP (2015) Ltd. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), LB Pharmaceuticals Inc (Sep 2025), Climb Bio, Inc. (Sep 2025)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
Watch Keros Therapeutics, Inc.
Get an email when Keros Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Keros Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Keros Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keros Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-22 | Out | Chief Financial Officer | 2026-08-03 | 8-K, 2026-07-22 | |
| 2026-07-22 | In | Controller | 2026-08-04 | 8-K, 2026-07-22 | |
| 2026-06-25 | In | Director | 8-K, 2026-06-25 |
Who leads Keros Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Controller: Annita Tanini, appointed, effective 2026-08-04 (filed 2026-07-22).
- Chief Financial Officer: Keith Regnante, departure reported, effective 2026-08-03 (filed 2026-07-22). No successor is named in these filings.
- Director: Anne Prener, appointed (filed 2026-06-25).
New leaders reset buying decisions — get the Full Report on Keros Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Keros Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Keros Therapeutics, Inc.Every change, in the filing's words
Departing: Keith Regnante, Chief Financial Officer, effective 2026-08-03
Executive Transition On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the "Company"), effective August 3, 2026 (the "Separation Date"), to pursue other opportunities.
Appointed: Annita Tanini, Controller, effective 2026-08-04
In connection with Mr. Regnante's departure, the Company's Board of Directors (the "Board") appointed Annita Tanini, the Company's Corporate Controller and Vice President, Finance, as the Company's interim principal financial officer and principal accounting officer, effective as of August 4, 2026.
- Mr. Regnante's resignation was voluntary and was not the result of any disagreement with the Company on any matter relating to the Company's accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices.
- The Company has commenced a search for a new Chief Financial Officer.
- Ms. Tanini, age 55, has served in finance leadership roles at the Company since May 2019, most recently as Corporate Controller and Vice President, Finance.
- From December 2015 to April 2017, she was the Vice President of Finance of Avedro, Inc., a commercial-stage ophthalmic medical technology company.
- Prior to that, Ms. Tanini was Senior Vice President of Finance of Fiksu, Inc., a mobile advertising and marketing technology company from March 2014 to November 2015.
- Previously, Ms. Tanini held Vice President of Finance roles at VideoIQ, Inc., MediaFriends, Inc., Jingle Networks Inc. and Arnold Worldwide LLC.
- Ms. Tanini holds a B.S. in finance and accounting, and an M.B.A. from the University of Massachusetts Lowell.
- Ms. Tanini's Compensation Arrangements In connection with Ms. Tanini's appointment, the Company and Ms. Tanini entered into an executive employment agreement, effective as of August 4, 2026 (the "Tanini Employment Agreement").
Appointed: Anne Prener, Director
Dr. Prener was appointed as a Class III director with a term expiring at the Company's 2029 annual meeting of stockholders.
- Appointment of Director On June 23, 2026, the board of directors (the "Board") of Keros Therapeutics, Inc. (the "Company"), based upon a recommendation from the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), voted to appoint Anne Prener, M.D., Ph.D., as a director of the Company, effective on July 1, 2026.
- Dr. Prener has not been appointed to a committee of the Board at this time.
- The shares subject to the Initial Option Grant will vest in equal quarterly installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant, subject to Dr. Prener's Continuous Service (as defined in the Plan) through each such vesting date.
- The Initial RSU Grant will vest over a three-year period, in twelve equal quarterly installments on each Quarterly Vesting Date (as defined below) that occurs on or following the effective date of Dr. Prener's appointment, subject to Dr. Prener's Continuous Service (as defined in the Plan) through each such vesting date.
- "Quarterly Vesting Date" means the 15th of each of February, May, August and November.
- Notwithstanding the foregoing, the Initial Option Grant and Initial RSU Grant will vest in full upon a Change in Control (as defined in the Plan).
Tools for this story
Each opens in a new tab, filled in for Keros Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.